Skip to main content
Springer Nature Link
Log in

Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

To analyze safety and efficacy of patterns of sorafenib and TACE therapy under real-life clinical practice conditions. A total of 338 Chinese patients with unresectable hepatocellular carcinoma (HCC) from the international database of the GIDEON non-interventional trial were included in this analysis. Endpoints were overall survival (OS), progression-free survival (PFS), time to progression (TTP) and safety. Two major patterns in the use of sorafenib observed in current Chinese clinical practice were: sorafenib administration subsequent to transarterial chemoembolization (TACE) treatment (n = 226, 66.9%) and sorafenib administration concomitant to TACE (n = 80, 35.4%). Patients receiving TACE prior to sorafenib had worse liver function (43.8% BCLC stage Cat diagnosis and 62.1% BCLC stage C at study entry) than those receiving TACE concomitant to sorefenib (35.0% BCLC stage C at diagnosis and 51.3% BCLC stage three at study entry). For patients undergoing prior TACE and concomitant TACE treatment, median OS time was 354 days vs. 608 days, PFS time was 168 days vs. 201 days, and TTP was 214 days vs. 205 days; and the percentage of patients who experienced drug-related adverse effects after sorafenib therapy in these two groups were 33.3 and 50.0%, respectively. Sorafenib treatment is usually administered in cases of tumor progression or poor liver function status after TACE treatment in China. Under such conditions, patients still gained a relatively satisfactory survival outcome. In addition, the present study suggests that concomitant sorafenib and TACE treatments may lead to a better prognosis, although differences in baseline characteristics may have contributed in part to the better outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+
from $39.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.

References

  1. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576

    Article  CAS  PubMed  Google Scholar 

  2. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr (2001) International trends and patterns of primary liver cancer. Int J Cancer 94:290–296

    Article  CAS  PubMed  Google Scholar 

  3. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Article  CAS  PubMed  Google Scholar 

  4. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

    Article  CAS  PubMed  Google Scholar 

  5. Peng S, Zhao Y, Xu F, Jia C, Xu Y, Dai C (2014) An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. PLoS One 9:e112530

    Article  PubMed  PubMed Central  Google Scholar 

  6. Abdel-Rahman O, Elsayed ZA (2013) Combination transarterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci 58:3389–3396

    Article  CAS  PubMed  Google Scholar 

  7. Han KH, Kudo M, Ye SL et al (2011) Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Int Soc Cell 81(Suppl 1):158–164

    Google Scholar 

  8. Kudo M, Imanaka K, Chida N et al (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47:2117–2127

    Article  CAS  PubMed  Google Scholar 

  9. Dai QS, Gu HL, Ye S, Zhang YJ, Lin XJ, Lau WY, Peng ZW, Chen MS (2014) Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: a retrospective comparative study. Mol Clin Oncol 2:1047–1054

    PubMed  PubMed Central  Google Scholar 

  10. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL (2002) A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94:1747–1752

    Article  PubMed  Google Scholar 

  11. Lencioni R, Marrero J, Venook A, Ye SL, Kudo M (2010) Design and rationale for the non-interventional global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) study. Int J Clin Pract 64:1034–1041

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lencioni R, Kudo M, Ye SL et al (2012) First interim analysis of the GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib) non-interventional study. Int J Clin Pract 66:675–683

    Article  CAS  PubMed  Google Scholar 

  13. Lencioni R, Kudo M, Ye SL et al (2014) GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): second interim analysis. Int J Clin Pract 68:609–617

    Article  CAS  PubMed  Google Scholar 

  14. Geschwind J-F, Kudo M, Marrero JA et al (2016) TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON. Radiology 279:630–640

    Article  PubMed  Google Scholar 

  15. Yang M, Yuan JQ, Bai M, Han GH (2014) Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Mol Biol Rep 41:6575–6582

    Article  CAS  PubMed  Google Scholar 

  16. Hu H, Duan Z, Long X, Hertzanu Y, Shi H, Liu S, Yang Z (2014) Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. PLoS One 9:e96620

    Article  PubMed  PubMed Central  Google Scholar 

  17. Turnes J, Diaz R, Hernandez-Guerra M et al (2015) Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain. Gastroenterol Hepatol 38:263–273

    Article  PubMed  Google Scholar 

  18. D’Angelo S, Germano D, Zolfino T et al (2015) Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy. Recenti Prog Med 106:217–226

    PubMed  Google Scholar 

  19. Saraswat VA, Pandey G, Shetty S (2014) Treatment algorithms for managing hepatocellular carcinoma. J Clin Exp Hepatol 4(Suppl 3):S80–S89

    Article  PubMed  PubMed Central  Google Scholar 

  20. Shao W, Zhang F, Cong N, Li J, Song J (2014) Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma. Oncol Lett 8:2263–2266

    PubMed  PubMed Central  Google Scholar 

  21. Qu XD, Chen CS, Wang JH et al (2012) The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer 12:263

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Colombo M, Sangiovanni A (2015) Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int 35(Suppl 1):129–138

    Article  CAS  PubMed  Google Scholar 

  23. Hu H, Duan Z, Long X et al (2015) Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study. PLoS One 10:e0117168

    Article  PubMed  PubMed Central  Google Scholar 

  24. Han G, Yang J, Shao G (2013) Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncol 9:403–410

    Article  CAS  PubMed  Google Scholar 

  25. Liu L, Chen H, Wang M, Zhao Y, Cai G, Qi X, Han G (2014) Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS One 9:e91124.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  PubMed  Google Scholar 

  27. Chao Y, Chung YH, Han G et al (2015) The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer 136:1458–1467

    Article  CAS  PubMed  Google Scholar 

  28. Lencioni R, Llovet J, Han G et al (2016) Sorafenib or placebo plus TACE with doxorubicin beads for intermediate stage HCC: the SPACE trial. J Hepatol 64:1090–1098

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chinese People’s Liberation Army General Hospital, Beijing, China

    Fengyong Liu & Zhijun Wang

  2. Fudan University Shanghai Cancer Center, Shanghai, China

    Zhiqiang Meng

  3. Zhejiang Cancer Hospital, Hangzhou, China

    Guoliang Shao

  4. Fudan University Zhongshan Hospital, Shanghai, China

    Jianhua Wang

  5. Second Military Medical University Changhai Hospital, Shanghai, China

    Jijin Yang

  6. Bayer Healthcare Company Ltd., Beijing, China

    Christina S M Yip & Dongfeng He

Authors
  1. Fengyong Liu
    View author publications

    Search author on:PubMed Google Scholar

  2. Zhiqiang Meng
    View author publications

    Search author on:PubMed Google Scholar

  3. Guoliang Shao
    View author publications

    Search author on:PubMed Google Scholar

  4. Jianhua Wang
    View author publications

    Search author on:PubMed Google Scholar

  5. Zhijun Wang
    View author publications

    Search author on:PubMed Google Scholar

  6. Jijin Yang
    View author publications

    Search author on:PubMed Google Scholar

  7. Christina S M Yip
    View author publications

    Search author on:PubMed Google Scholar

  8. Dongfeng He
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Jianhua Wang.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest.

Research involving human participants and/or animals

This study recruited a subgroup of Chinese patients from the international database of the GIDEON trial. The study was approved by local ethics committees and institutional review boards.

Informed consent

Informed consent was obtained from all patients, and all patients met the inclusion and exclusion criteria and were treated with sorafenib at least once.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, F., Meng, Z., Shao, G. et al. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study. Mol Biol Rep 44, 149–158 (2017). https://doi.org/10.1007/s11033-016-4092-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-016-4092-x

Keywords